Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease.

To assess the neurobiological substrate of initial cognitive decline in Parkinson's disease (PD) to inform patient management, clinical trial design, and development of treatments.We longitudinally assessed, up to 3 years, 423 newly diagnosed patients with idiopathic PD, untreated at baseline,...

Full description

Bibliographic Details
Main Authors: Chelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, I-Wei Wu, Yu Zhang, Mike Nalls, Andrew Singleton, Leslie A Shaw, Ju-Hee Kang, John Q Trojanowski, Andrew Siderowf, Christopher Coffey, Shirley Lasch, Dag Aarsland, David Burn, Lana M Chahine, Alberto J Espay, Eric D Foster, Keith A Hawkins, Irene Litvan, Irene Richard, Daniel Weintraub, Parkinson’s Progression Markers Initiative (PPMI)
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5435130?pdf=render

Internet

http://europepmc.org/articles/PMC5435130?pdf=render

Similar Items